Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Biodegradable Balloon to Revolutionize Rectal Protection from Toxicity during Prostate Cancer Radiation Therapy

By HospiMedica International staff writers
Posted on 30 Aug 2023

Prostate cancer stands as the most common non-skin cancer detected in men and ranks as the second leading cause of male cancer-related deaths, following lung cancer. With a prevalence of 1 in 9 men receiving a prostate cancer diagnosis during their lifetime, over 1.4 million men are globally diagnosed annually. The course of prostate cancer treatment hinges on various factors including cancer growth rate, extent of spread, overall patient health, and potential treatment benefits or side effects. Treatment options like surgery or radiation may be recommended based on evolving test results. However, prostate radiation therapy often leads to a concerning issue – rectal toxicity, a consequence of the close proximity between the prostate and rectum. Despite advanced technology and precise planning, prostate movement during sessions exposes parts of the rectal wall to high radiation doses, resulting in rectal toxicity or proctitis. Hence, there is a strong need for a solution that protects the rectum from the detrimental effects of high-dose radiation. Now, a biodegradable balloon dramatically reduces the chance of rectal toxicity by protecting the adjacent healthy tissues from harmful radiation, thereby minimizing adverse procedural events.

BioProtect Ltd.’s (Tzur Yigal, Israel) BioProtect Balloon Implant System is an implantable, biodegradable balloon that creates a defined, enclosed distance to minimize radiation exposure to the rectum during prostate radiation therapy. Through its distinct design, the new generation balloon achieves up to 18mm separation between the rectal wall and the treatment area prior to initiating radiation therapy. The implantation process involves a minimally invasive, needle-free insertion technique for guiding the balloon using ultrasound with either local or general anesthesia. Once in place between the prostate and rectum, the balloon is filled with sterile saline and positioned to achieve its final, well-defined configuration.

By maintaining a consistent separation between the prostate and rectum, the balloon remains visible across various imaging modalities including CT, MRI, and ultrasound. It forms a protective barrier, allowing for safe radiation therapy. The balloon maintains its size and shape within the body throughout the radiation course, naturally biodegrading over time (typically within six months after implantation), thus negating the need for a separate removal procedure. The BioProtect Balloon Implant System has received clearance from the US FDA.

"We believe that our balloon has the potential to revolutionize rectal protection from toxicity during prostate cancer radiation therapy," said Itay Barnea, CEO of BioProtect. "Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy."

Related Links:
BioProtect Ltd. 

Gold Member
12-Channel ECG
CM1200B
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Illuminated Retractor System
HandLite
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Heart failure is a serious condition where the heart cannot pump sufficient blood to meet the body's needs, leading to symptoms like fatigue, weakness, and swelling in the legs and feet, and it can ultimately... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.